Potential biomarkers and immune characteristics of small bowel adenocarcinoma

被引:0
作者
Jinggao Feng
Xiayu Tang
Liusong Song
Zhipeng Zhou
Yuan Jiang
Yao Huang
机构
[1] The Central Hospital of Yongzhou,Department of Gastrointestinal and Anorectal Surgery
来源
Scientific Reports | / 12卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Small bowel adenocarcinoma (SBA) is a gastrointestinal malignancy with low incidence but poor prognosis, and its pathogenesis is still unclear. This study aimed to explore potential disease-causing biomarkers of SBA. The gene expression datasets of SBA and normal samples were downloaded from the Gene Expression Omnibus database. First, differential gene expression analysis and weighted gene coexpression network analysis (WGCNA) were performed. Common genes (CGs) were obtained by intersection of differentially expressed genes (DEGs) and optimal modal genes of WGCNA. Subsequently, a protein‒protein interaction network was established to screen hub genes, and target genes were obtained by Lasso regression analysis of hub genes. An SBA risk prediction model was established based on target genes. The prediction accuracy of the model was evaluated by the area under the receiver operating characteristic curve (AUC). The levels of immune cell infiltration and activation of immune pathways were compared between SBA and normal samples using the "ggpubr" and "reshape2" packages. A total of 1058 DEGs were identified. WGCNA showed that the signature gene in the brown module was significantly associated with SBA (p = 7E−17), and 469 CGs were obtained. Four target genes (APOA4, APOB, COL1A2, FN1) were identified and showed excellent prediction of SBA risk (AUC = 0.965). In addition, active dendritic cells and macrophages showed higher infiltration levels in SBA. Meanwhile, the APC_co_stimulation pathway and parainflammation pathway were strongly active in SBA. Four target genes (APOA4, APOB, COL1A2, FN1) may be involved in the pathogenesis of small bowel adenocarcinoma.
引用
收藏
相关论文
共 392 条
  • [1] Moati E(2022)Therapeutic strategies for patients with advanced small bowel adenocarcinoma: Current knowledge and perspectives Cancers 14 1-33
  • [2] Overman MJ(2021)Cancer statistics, 2021 CA Cancer J. Clin. 71 7-977
  • [3] Zaanan A(2020)Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients Int. J. Cancer 147 967-2706
  • [4] Siegel RL(1999)The American College of Surgeons Commission on Cancer and the American Cancer Society: Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985–1995 Cancer 86 2693-190
  • [5] Miller KD(2004)Prognostic significance of microsatellite instability in curatively resected adenocarcinoma of the small intestine Cancer Lett. 203 181-544
  • [6] Fuchs HE(2013)Small bowel adenocarcinomas–existing evidence and evolving paradigms Nat. Rev. Clin. Oncol. 10 534-176
  • [7] Jemal A(2013)Combined loss of E-cadherin and aberrant beta-catenin protein expression correlates with a poor prognosis for small intestinal adenocarcinomas Am. J. Clin. Pathol. 139 167-1553
  • [8] Aparicio T(2017)genomic profiling of small-bowel adenocarcinoma JAMA Oncol. 3 1546-1746
  • [9] Henriques J(2014)ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma Eur. J. Cancer 50 1740-308
  • [10] Manfredi S(2018)Exome-wide somatic mutation characterization of small bowel adenocarcinoma PLoS Genet. 14 1-1694